ABSTRACT BACKGROUND Evidence suggests that interleukin (IL)-1b is important in the pathogenesis of atherosclerosis and its
.
In addition to its key role in vascular disease, has been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM). IL-1RA expression is reduced in pancreatic islets of patients with T2DM, and high glucose concentrations induce the production of IL-1b in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis (15) . Blockade of the interleukin-1 receptor with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation in patients with T2DM (16) . Patients with T2DM are at high risk for cardiovascular disease (17) and have evidence of both increased plaque inflammation (18) and reduced arterial distensibility (19) .
This group might, therefore, derive "metabolic" and 
Vascular magnetic resonance imaging (MRI) has
emerged as a precise, highly reproducible, and versatile tool to assess both vascular structure and function at multiple arterial loci (22) (23) (24) (25) . Accordingly, we designed a randomized, placebo-controlled Phase 
METHODS
Novartis Pharmaceuticals (Cambridge, Massachusetts) initiated this Phase II, double-blind, randomized, placebo-controlled trial, with the final study protocol designed in collaboration with the investigators (R.P.C., J.-C.T., and Z.A.F.), based on their previously published methods (19, 23, 24) . The study was undertaken at 9 centers in Canada, the United Kingdom, All authors had full access to all the data in the study and assume responsibility for publication.
All statistical analyses were performed by using Stata 14 (StataCorp LP, College Station, Texas).
RESULTS
Of 450 patients screened, 189 were randomized to receive either placebo (n ¼ 94) or canakinumab 150 mg (n ¼ 95). The proportions of patients with diabetes, duration of diabetes, and glycemic control (estimated from HbA1 c ) were similar in the groups, and there was a high prevalence for each of hypertension, dyslipidemia, and background coronary artery disease (Table 1) ; the latter was slightly higher proportionately in the placebo group. There was no Table 2 ). The most common cause for discontinuation was for adverse events. A full list of adverse events is provided in Online Table 1 . Seven patients withdrew consent, and 7 patients were excluded from analysis due to significant protocol deviation.
As a biomarker of atherosclerotic plaque burden, vessel wall area was quantified in the aorta and carotid arteries ( There was no statistically significant difference in wall area between canakinumab treatment and placebo at any of the 3 aortic sites at either 3 or 12 months.
Aortic distensibility was calculated from measurements made at 3 sites in the aorta. There were no statistically significant differences between canakinumab treatment and placebo for change in aortic distensibility, and no significant changes occurred in systolic or diastolic blood pressure at either 3 or 12 months of treatment versus baseline. There were also no significant differences in measures of PWV between these 2 groups at either time point (Table 3) . Table 2 .
Choudhury et al. Canakinumab had no effect on fasting glucose, HbA 1c , or measures of insulin sensitivity.
O C T O B E R
In common with earlier studies (19, 23, 24) , atherosclerosis burden was quantified in the common carotid arteries and the aorta. We found no statisti- Moreover, measurements were made separately on individual slices, but the data presented are for In common with previous studies, we chose to quantify vessel wall area in the tubular carotid arteries because they are less susceptible to error in serial measurements due to "volume averaging"
effects. Previously described techniques allow plaque lipid quantification with the use of T2 mapping, but these were not current at the time of protocol design (27) . Lipid elements may be the most readily mobilized components of atherosclerotic plaque, although the mechanisms by which IL-1b inhibition might affect plaque lipid are not clear. *Change from baseline, not log-transformed. LSMs of outcomes (95% CIs) with number of patients reported from the analysis of covariance of the log-transformed outcome at 3 and 12 months, adjusted for log-transformed baseline of outcome and including the 2-level factor type 2 diabetes mellitus or impaired glucose tolerance as a covariate. Inclusion of patients is according to the protocol. The treatment effect is reported as the difference between the canakinumab arm and the placebo arm and after back-transforming the treatment effect as the ratio of the levels in the canakinumab arm to the placebo arm. The LSMs are back-transformed (geometric means).
Abbreviations as in Tables 1 and 3 . (35) . There was also a marginal but statistically significant elevation in total cholesterol levels, with an increase by 18.5 mg/dl after 3 months' treatment.
Conversely, lipoprotein(a) was significantly reduced by canakinumab at both time points.
STUDY LIMITATIONS. This study did not evaluate atherosclerosis at the carotid bifurcation, where the burden of disease is often greatest, nor did it quantify plaque lipid content. Although MRI scans provide highly reproducible measures of plaque structure and vessel function, they offer no direct measure of plaque inflammation. It is possible for drugs to markedly affect plaque biology without altering plaque size, particularly on short-term follow-up (36) . In this study, no attempt was made to select subjects on the basis of inflammatory status. More refined patient selection may enhance the effectiveness of drugs that are directed toward specific processes and pathways. Finally, we cannot exclude the possibility that the dose of canakinumab was not high enough to generate a maximal effect on atherosclerotic burden, although the dose was sufficient to lower both hs-CRP and IL-6 levels.
There were no significant differences in adverse events between the 2 groups, nor were any unex- Choudhury et al.
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